Enhancing the Bioavailability of Low-Solubility Compounds
|
Low aqueous solubility resulting in poor oral bioavailability of drug candidates is recognised as an increasingly common challenge facing the pharmaceutical industry. An estimated 25% to 30% of compounds in early development have poor bioavailability due to low solubility, representing a significant loss in therapeutic and economic opportunity.
In this complimentary case study webcast, Bend Research discusses amorphous dispersion based formulations highlighting:
- Outlining the need for increased solubility and rapid absorption
- Assessing the impact of enteric dispersions on absorption rate
- Developing rapidly dissolving amorphous formulations
- Pursuing formulation and process development for amorphous drugpolymer nanoparticles
Presenter:
|
Dana Settell
Director of Business Development Bend Research, Inc |
Advertisement
* = required.
Not a member yet? Sign up
|
Reach Pharma professionals through cost-effective marketing opportunities to deliver your message, position yourself as a thought leader, and introduce new products, techniques and strategies to the market.
Learn More >> Learn how to sponsor a webinar with us? Join today and interact with a vibrant network of pharma professionals, keeping up to date with the pharma industry by accessing our wealth of Pharma articles, videos, online seminars, live conferences and more. Sign Up Today! |
| Pharma IQ, a division of IQPC 2013 All rights reserved. Use of this site constitutes acceptance of our User Agreement and Privacy Policy. Careers With IQPC | Contact Us | Unsubscribe to Bizo | About Us | Cookie Policy |
|
Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!